# Nicoletta Colombo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nicoletta-colombo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,929 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 101 |
| i10-index | 383 |
| Last Known Institution | European Institute of Oncology |
| OpenAlex ID | https://openalex.org/A5103127347 |
| ORCID iD | 0000-0003-2225-715X |
| Works | 804 |

## Researcher papers

Showing 12 of 25.

- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer](https://scholariq.org/papers/olaparib-plus-bevacizumab-as-first-line-maintenance-in-ovarian-cancer/)
- [ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma](https://scholariq.org/papers/esgo-estro-esp-guidelines-for-the-management-of-patients-with-endometrial/)
- [Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/olaparib-tablets-as-maintenance-therapy-in-patients-with-platinum-sensitive/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer-diagnosis-treatment/)
- [Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial](https://scholariq.org/papers/paclitaxel-plus-platinum-based-chemotherapy-versus-conventional-platinum-based/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/newly-diagnosed-and-relapsed-epithelial-ovarian-carcinoma-esmo-clinical-practice/)
- [Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer](https://scholariq.org/papers/pembrolizumab-for-persistent-recurrent-or-metastatic-cervical-cancer/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer/)
- [Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup](https://scholariq.org/papers/evaluation-of-new-platinum-based-treatment-regimens-in-advanced-stage-ovarian/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)

## Researcher university

- [European Institute of Oncology](https://scholariq.org/institutions/european-institute-of-oncology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.